Abstract
Multiple myeloma (MM) is most frequently diagnosed among patients aged 65-74. Autologous stem cell transplantation (ASCT) is considered as standard of care for patients younger than 65 years but limited data are available on outcome of ASCT for patients beyond 65 years.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
